Acne Prone Skin

This pilot cohort study evaluates changes in skin surface appearance in adult participants with acne-prone skin during and following a standardized five-session course of PRX S (WiQo SpA), a topical cosmetic product designed for oily and acne-prone skin. The study asks whether a standardized in-office PRX S treatment cycle - five sessions administered at two-week intervals and complemented by a prescribed home care regimen - is associated with observable changes in objective skin surface parameters (pore appearance, texture, spots, redness, porphyrins), clinician-rated acne severity (IGA, GAGS), and participant-reported skin-related quality of life (QoL-RA) in adults with acne-prone skin. Using a single-group, pre-post observational design across two U.S. sites (Leawood, KS and Tulsa, OK), 30 participants will undergo VISIA complexion analysis and clinical assessments at baseline (T0), mid-cycle (T1, Week 6), and end of follow-up (T2, Week 10). No single primary endpoint is designated; all analyses are explicitly exploratory.

The goal of this clinical trial is to evaluate the dermatological and ophthalmological safety of a cosmetic product and to assess its comedogenic and acnegenic potential in participants with oily or acne-prone skin. The main questions it aims to answer are: * Does the investigational product demonstrate an absence of comedogenic potential under normal conditions of use? * Does the investigational product demonstrate an absence of acnegenic potential under normal conditions of use? * Does the investigational product demonstrate dermatological and ophthalmological acceptability? * Does the investigational product present a low risk of irritation or discomfort during the study period? Participants will: * Apply the investigational cosmetic product to the face and body twice daily for 28 days. * Undergo dermatological evaluations to assess skin tolerability and identify any signs of irritation or adverse reactions. * Undergo ophthalmological evaluations to assess ocular tolerability. * Undergo clinical assessments to evaluate the comedogenic and acnegenic potential of the investigational product. The study will enroll 33 male and female participants aged 18 to 45 years with oily or acne-prone skin. Participants will be followed for 28 days while using the investigational product according to the study protocol.